Ligand Pharmaceuticals develops and licenses biopharmaceutical assets worldwide. Commercial programs include Kyprolis, Evomela, Rylaze, Filspari, Teriparatide, Vaxneuvance, Pneumosil, and others. Products also include TZIELD, Nexterone, Zulresso, Veklury, Noxafil-IV, Duavee, Exemptia, Vivitra, Bryxta, and Zybev. The company has alliances with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand also sells Captisol materials.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 251.2 |
| Price/Free Cash Flow' | 37.8 |
| ROIC | 11.6% |
| Net Debt/EBITDA | -5.7 |